Angiotensin-converting enzyme 2 (ACE2) gene methylation (ACE2 methylation)

Angiotensin-converting enzyme 2 (ACE2) gene methylation is a critical epigenetic modification that regulates the expression levels of the ACE2 protein, which serves as the primary entry receptor for coronaviruses such as SARS-CoV-2. DNA methylation at CpG islands within the ACE2 promoter region acts as a molecular switch; hypermethylation typically leads to gene silencing and reduced receptor density, while hypomethylation facilitates higher expression and increased susceptibility to viral infection [1, 4, 10]. This regulatory mechanism is a key determinant of individual susceptibility to COVID-19, with studies highlighting that factors like age, sex, and underlying conditions such as hypertension or obesity significantly influence methylation patterns [1, 3, 5]. Beyond its role in viral entry, ACE2 is a vital enzyme in the renin-angiotensin system (RAS) responsible for converting the vasoconstrictor Angiotensin II into the vasodilator Angiotensin-(1-7), thereby protecting against cardiovascular, renal, and pulmonary damage [14, 15]. Therapeutic interest centers on utilizing epigenetic modifiers or targeted peptides, such as NACE2i, to induce a protective methylation signature that reduces viral load and mitigates inflammatory responses [11]. However, clinical targeting of ACE2 methylation faces challenges in achieving specificity and maintaining the enzyme's homeostatic role in cardiovascular protection [12].

Other names

ACE2 DNA methylationACE2 promoter methylationEpigenetic regulation of ACE2Angiotensin-converting enzyme 2 gene silencing

Modulation of DNA methyltransferase (DNMT) activity or targeted recruitment of epigenetic modifiers to the ACE2 promoter to alter mRNA transcription and subsequent surface receptor density.